Alveolus Bio, which is developing inhaled therapies for the treatment of respiratory diseases, announced that Indian API manufacturer and CDMO Shilpa Medicare Limited has led a strategic financing round that will fund Phase 2 development of of its lead candidate. As part of the deal, Shilpa subsidiary Shilpa Biologics will partner with Alveolus Bio for development and manufacturing of Alveolus products, which include inhaled live biotherapeutics.
A spin-off from the University of Alabama Birmingham, Alveolus Bio is developing a pipeline of therapies targeted to the deep lung that are based on its resMIT (respiratory microbiota-based inhaled therapeutics) platform. The pipeline includes products for the treatment of COPD, bronchopulmonary dysplasia, and pulmonary fibrosis.
Alveolus Bio CEO Gaurav Mehta commented, “Securing Shilpa as our lead investor is a transformative step. Their global pharmaceutical leadership aligns perfectly with our vision to redefine how lung diseases are treated.”
Chief Scientific Officer Vivek Lal said, “Alveolus Bio’s breakthrough science is poised to transform respiratory care. Through this strategic partnership with Shilpa, we combine disruptive biotech innovation with world-class commercialization, bringing life-changing therapies faster to the market.”
Shilpa Medicare Managing Director Vishnukant Bhutada said, “Shilpa has always focused on enabling breakthrough biologics. This partnership strengthens our innovation pipeline and reinforces our role as a trusted global partner for biotech development.”
Read the Alveolus Bio press release
